Literature DB >> 17971603

Response of intracranial metastases to erlotinib therapy.

M Houman Fekrazad1, Meera Ravindranathan, Dennie V Jones.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2007        PMID： 17971603     DOI： 10.1200/JCO.2007.13.3751

Source DB:  PubMed          Journal:  J Clin Oncol        ISSN： 0732-183X            Impact factor:   44.544


× No keyword cloud information.
  23 in total

Review 1.  Epidermal growth factor receptor tyrosine kinase inhibitors for the treatment of central nervous system metastases from non-small cell lung cancer: the present and the future.

Authors:  Claudia Proto; Martina Imbimbo; Rosaria Gallucci; Angela Brissa; Diego Signorelli; Milena Vitali; Marianna Macerelli; Giulia Corrao; Monica Ganzinelli; Francesca Gabriella Greco; Marina Chiara Garassino; Giuseppe Lo Russo
Journal:  Transl Lung Cancer Res       Date:  2016-12

Review 2.  Non-small cell lung cancer (NSCLC) and central nervous system (CNS) metastases: role of tyrosine kinase inhibitors (TKIs) and evidence in favor or against their use with concurrent cranial radiotherapy.

Authors:  Panagiota Economopoulou; Giannis Mountzios
Journal:  Transl Lung Cancer Res       Date:  2016-12

Review 3.  The biology of brain metastases-translation to new therapies.

Authors:  April F Eichler; Euiheon Chung; David P Kodack; Jay S Loeffler; Dai Fukumura; Rakesh K Jain
Journal:  Nat Rev Clin Oncol       Date:  2011-04-12       Impact factor: 66.675

4.  Characteristics of patients with brain metastases from lung cancer in a palliative care center.

Authors:  Ryuya Yamanaka; Hatsuyo Koga; Yousuke Yamamoto; Shinichi Yamada; Tomomi Sano; Tetsushi Fukushige
Journal:  Support Care Cancer       Date:  2010-03-10       Impact factor: 3.603

5.  An unusual response with long term survival using erlotinib in NSCLC lung with brain metastases.

Authors:  Madhup Rastogi; Sambit Swarup Nanda; Chandra Prakash; Dinkar Kulshreshtha
Journal:  BMJ Case Rep       Date:  2016-01-04

Review 6.  Role of epidermal growth factor receptor in lung cancer and targeted therapies.

Authors:  Tie-Cheng Liu; Xin Jin; Yan Wang; Ke Wang
Journal:  Am J Cancer Res       Date:  2017-02-01       Impact factor: 6.166

7.  Survival of patients with brain metastases from non-small cell lung cancer harboring EGFR mutations treated with epidermal growth factor receptor tyrosine kinase inhibitors.

Authors:  Jumpei Kashima; Yusuke Okuma; Maki Miwa; Yukio Hosomi
Journal:  Med Oncol       Date:  2016-10-18       Impact factor: 3.064

8.  Erlotinib therapy in a patient with non-small-cell lung cancer and brain metastases.

Authors:  Giuseppe Altavilla; Carmela Arrigo; Maria Carmela Santarpia; Giuseppe Galletti; Giovanni Picone; Grazia Marabello; Chiara Tomasello; Vincenzo V Pitini
Journal:  J Neurooncol       Date:  2008-06-20       Impact factor: 4.130

Review 9.  Oral Targeted Therapies and Central Nervous System (CNS) Metastases.

Authors:  Michael P Gabay; Scott M Wirth; Joan M Stachnik; Colleen L Overley; Katie E Long; Linda R Bressler; John L Villano
Journal:  CNS Drugs       Date:  2015-11       Impact factor: 5.749

10.  Good Clinical Response to Erlotinib in a Non-Small Cell Lung Cancer Patient Harboring Multiple Brain Metastases and a Double Active Somatic Epidermal Growth Factor Gene Mutation.

Authors:  Katsuhiro Masago; Yosuke Togashi; Masahide Fukudo; Tomohiro Terada; Kaoru Irisa; Yuichi Sakamori; Shiro Fujita; Young Hak Kim; Tadashi Mio; Ken-Ichi Inui; Michiaki Mishima
Journal:  Case Rep Oncol       Date:  2010-04-22
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.